Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes
Executive Summary
Advisory committee votes 8-7 against approval of the novel opioid; several members say they would change their vote with more data.
You may also be interested in...
Keeping Track: Veklury NDA Arrives At US FDA; Olinvyk Sees Approval; MAb Filings By Regneron, Y-mAbs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Keeping Track: Seqirus Pandemic Flu Vaccine Approved; Trevena Resubmits Oliceridine
The latest drug development news and highlights from our US FDA Performance Tracker.
Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans
US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.